Whalen Wealth Management Inc. Makes New Investment in McKesson Corporation $MCK

Whalen Wealth Management Inc. purchased a new position in shares of McKesson Corporation (NYSE:MCK) during the 3rd quarter, HoldingsChannel reports. The firm purchased 675 shares of the company’s stock, valued at approximately $576,000.

A number of other hedge funds also recently bought and sold shares of MCK. Elm3 Financial Group LLC increased its stake in shares of McKesson by 18.4% during the third quarter. Elm3 Financial Group LLC now owns 374 shares of the company’s stock worth $319,000 after buying an additional 58 shares during the period. Moody National Bank Trust Division grew its holdings in McKesson by 4.9% during the 3rd quarter. Moody National Bank Trust Division now owns 1,433 shares of the company’s stock worth $1,224,000 after acquiring an additional 67 shares in the last quarter. Rosenberg Matthew Hamilton raised its holdings in shares of McKesson by 2.8% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 406 shares of the company’s stock valued at $347,000 after purchasing an additional 11 shares in the last quarter. Baker Tilly Wealth Management LLC lifted its position in shares of McKesson by 11.3% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 394 shares of the company’s stock worth $337,000 after purchasing an additional 40 shares during the last quarter. Finally, Ferguson Wellman Capital Management Inc. grew its stake in shares of McKesson by 1.6% during the third quarter. Ferguson Wellman Capital Management Inc. now owns 28,674 shares of the company’s stock worth $24,482,000 after purchasing an additional 438 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insiders Place Their Bets

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of McKesson stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the transaction, the chief accounting officer directly owned 521 shares in the company, valued at approximately $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The disclosure for this sale is available in the SEC filing. Insiders own 0.06% of the company’s stock.

McKesson Price Performance

Shares of MCK traded up $17.15 during midday trading on Thursday, reaching $927.48. 252,474 shares of the stock were exchanged, compared to its average volume of 936,417. McKesson Corporation has a twelve month low of $723.68 and a twelve month high of $999.00. The company has a market capitalization of $108.13 billion, a price-to-earnings ratio of 24.80, a PEG ratio of 1.83 and a beta of 0.30. The business’s 50-day moving average price is $882.32 and its 200 day moving average price is $832.73.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. The firm had revenue of $105.38 billion during the quarter, compared to analysts’ expectations of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the firm earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, equities research analysts expect that McKesson Corporation will post 44.73 earnings per share for the current fiscal year.

McKesson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. This is a boost from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date was Tuesday, September 1st. McKesson’s payout ratio is 10.06%.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Strategic Option Care Health investment: McKesson and Clayton, Dubilier & Rice agreed to acquire Option Care Health for approximately $5.8 billion, including debt. McKesson plans to invest about $1.4 billion for a 49% stake, giving it exposure to the expanding home- and outpatient-infusion market. Option Care shareholders would receive $32.05 per share, representing a premium of roughly 37% before the deal was announced. The transaction remains subject to shareholder and regulatory approvals. CD&R and McKesson ink $5.8bn take-private deal for Option Care Health
• Positive Sentiment: Higher analyst price target: Leerink Partners raised its McKesson target from $1,030 to $1,070 and maintained an “outperform” rating, implying meaningful additional upside based on the referenced trading level. McKesson also received a consensus “moderate buy” recommendation from analysts. Leerink Partners Adjusts Price Target on McKesson to $1,070
• Positive Sentiment: Growth profile remains supportive: Recent coverage highlights McKesson’s above-average earnings growth, favorable Wall Street views and potential benefits from artificial-intelligence adoption. The company’s latest quarter also exceeded consensus estimates for revenue and earnings, while management’s fiscal 2027 EPS guidance supports continued profit growth. Here’s Why McKesson is a Strong Growth Stock
• Neutral Sentiment: The Option Care transaction could strengthen McKesson’s healthcare-services portfolio, but investors will monitor the $1.4 billion capital commitment, integration plans and regulatory approval. McKesson’s thin net margin and elevated valuation also leave less room for execution disappointments.

Analysts Set New Price Targets

A number of analysts have weighed in on MCK shares. Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, September 4th. Barclays increased their price objective on McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a report on Wednesday, August 19th. TD Cowen raised their target price on McKesson from $989.00 to $1,006.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. UBS Group boosted their target price on McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $845.00 price target on shares of McKesson in a report on Monday, September 14th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $973.19.

McKesson Profile

McKesson Corporation (NYSE:MCK) is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson’s principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.